GEMTESA IS A SELECTIVE BETA-3 ADRENERGIC AGONIST1,2

IN VITRO RECEPTOR BINDING ASSAY DATA*
Beta-adrenergic receptor subtype GEMTESA (% activity)
Beta-1 0
Beta-2 2.0
Beta-3 104.0

*Clinical relevance of this in vitro receptor binding assay data is unknown.

At 10 µM (exceeds mean human Cmax values of GEMTESA by ~30x).1,2

Cmax=maximum serum concentration.

By activating the beta-3 adrenergic receptors, GEMTESA relaxes the bladder detrusor muscle to increase capacity and reduce OAB symptoms1,3

GEMTESA is a selective human beta-3 adrenergic receptor agonist. Bladder relaxation is predominantly mediated by beta-3 adrenergic receptors1,4

Diagram of a bladder. GEMTESA® activates the beta-3 adrenergic receptor, relaxing the bladder detrusor muscle.diagram of bladder

Take a look at the use of GEMTESA with
other prescribed medications

Drug interactions
Doctor prepared to discuss GEMTESA and OAB with patients.
 

References: 1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Data on file. Urovant Sciences GmbH. 3. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609-623. 4. Yamaguchi O, Chapple CR. β3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26(6):752-756. doi:10.1002/nau.20420